Loading...

PE anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1
LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
  • GL-1
    LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
105007 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105008 200 µg 235€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References

(PubMed link indicates BioLegend citation)
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  3. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  4. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  5. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  6. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  7. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  8. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  9. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  10. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  11. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  12. Saito S, et al. 2020. Nutrients. 12:. PubMed
  13. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  14. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  15. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  16. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  17. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  18. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  19. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  20. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  21. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  22. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  23. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  24. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  25. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  26. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  27. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  28. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  29. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  30. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  31. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  32. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  33. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  34. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  35. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  36. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  37. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  38. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  39. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  40. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  41. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  42. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  43. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  44. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  45. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  46. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  47. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  48. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  49. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  50. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  51. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  52. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  53. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  54. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  55. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  56. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  57. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  58. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  59. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  60. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  61. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  62. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  63. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  64. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  65. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  66. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  67. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  68. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  69. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  70. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  71. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  72. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  73. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  74. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  75. Tran NL, et al. 2022. Elife. 11:. PubMed
  76. Li H, et al. 2022. iScience. 25:104481. PubMed
  77. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  78. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  79. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  80. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  81. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  82. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
  83. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  84. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  85. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  86. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
RRID
AB_313150 (BioLegend Cat. No. 105007)
AB_313151 (BioLegend Cat. No. 105008)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account